Evidence map›Paper›PMID 42499651›Full record

ArticleJHLT open2026

Outcomes of lung transplantation using TorEx ex-vivo lung perfusion.

Haruchika Yamamoto, Aadil Ali, Gabriel Siebiger, Elliot Wakeam, Laura Donahoe, Jonathan C Yeung, Andrew Pierre, Marc de Perrot, Kazuhiro Yasufuku, Thomas K Waddell and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haruchika YamamotoToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Aadil AliToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Gabriel SiebigerToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Elliot WakeamToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Laura DonahoeToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Jonathan C YeungToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Andrew PierreToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Marc de PerrotToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Kazuhiro YasufukuToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Thomas K WaddellToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Shaf KeshavjeeToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
Marcelo CypelToronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Ex-vivo lung perfusion (EVLP) has expanded donor lung utilization, with over 1000 cases performed at our center since 2008. A next-generation Toronto EVLP system (TorEx EVLP) was introduced in December 2022, enabling simplified circuit setup by loading an organ chamber into an all‑in‑one device, potentially facilitating EVLP use at less experienced centers. This study reports the initial experience with TorEx EVLP and compares outcomes with (1) first‑generation EVLP and (2) conventional lung transplantation without EVLP. Methods: In this single-center retrospective cohort study, 1067 EVLP procedures were performed from September 2008 to September 2024 (first-generation EVLP [G1], n=874; TorEx EVLP [G2], n=193). Post-transplant short- and long-term outcomes were compared among G1, G2, and contemporaneous direct transplants without EVLP (direct, n=1575). Results: Of 1067 EVLP cases, 684 were accepted for transplant (utilization: G1 64.4%, G2 62.7%), and 700 transplants were performed (including 16 split singles). G1 and G2 had significantly higher DCD donor use (direct vs G1 vs G2: 17% vs 48% vs 60%, p<0.001) and lower donor P/F ratios (422 vs 368 vs 368 mmHg, p<0.001). Recipients in G1 and G2 were older than direct recipients (59 vs 61 vs 65 years, p<0.05). Post‑transplant outcomes were similar across groups, including PGD3 at 72 h (15% vs 16% vs 10%, p=0.21), extubation within 72 h (65% vs 64% vs 68%, p=0.67), overall survival, and CLAD‑free survival. Conclusions: Despite higher-risk donor use, outcomes with both first- and next-generation Toronto EVLP systems were comparable to direct transplantation.

Indexed as

Ex-vivo lung perfusionLung transplantationNext-generation EVLPOutcomeTorEXToronto EVLP system

Identifiers

PMID42499651
PMCPMC13396924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.